Kumar Srinivasan

Biography

Kumar joined AstraZeneca in April 2012 to head up business development for the newly-constituted AZ Neuro group and was promoted to his current role in March 2013 as Head of Scientific Partnering and Alliances. In his most recent external position, Kumar was Chief Business Officer at Probiodrug AG, then a private venture funded German company developing novel treatment for Alzheimer’s and inflammatory diseases. Prior to joining Probiodrug, Kumar was Vice-President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre-phase 2 opportunities for several therapeutic areas.

Research Interest

Alzheimer’s and inflammatory diseases